



MARKET RELEASE

11 October 2011

PROBIOMICS LIMITED

SUSPENSION FROM OFFICIAL QUOTATION

The securities of Probiomics Limited (the "Company") will be suspended from quotation immediately, following the announcement of the Company's proposed merger with Hunter Immunology Limited.

Unless ASX decides otherwise, the Company's securities will be reinstated to quotation prior to the commencement of trading on Wednesday, 12 October 2011.

In accordance with ASX's requirements for compliance with Chapter 11 of the Listing Rules, if shareholders approve the proposed change of activities, it is expected that the Company's securities will be suspended from quotation immediately following such approval and will remain suspended until the Company has complied with Chapters 1 and 2 of the Listing Rules.

For further details, please refer to the Company's announcement.

Security Code: PCC

A handwritten signature in black ink, appearing to read 'Elvis Onyura', is written over a circular stamp that contains a grid pattern.

Elvis Onyura
Adviser, Listings (Sydney)

10 October 2011

Our Ref: DPS:PRO005/4001

Mr Cameron Bill
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

TELEPHONE +61 2 8915 1000
FACSIMILE +61 2 8916 2000
Level 12
60 Carrington Street
Sydney NSW Australia
GPO Box 1433 Sydney
NSW 2001 Australia
DX 262 Sydney
ABN 55 365 334 124

By email

Dear Cameron

Probiomics Limited ACN 084 464 193

We have been instructed on behalf of our client Probiomics Limited (ASX Code: PCC) (**Probiomics**) to request a suspension in its securities for a period of one (1) trading day, commencing upon the release of an announcement of the Proposed Transaction (as described below), that will occur on 11 October, 2011 (**Announcement**).

In accordance with ASX Listing Rule 17.2, we advise ASX as follows:

- (a) the reasons for the request for a suspension is to permit shareholders in Probiomics and the market generally the opportunity to consider the substance of the content of the Announcement in connection with a proposed major acquisition which will also involve a capital raising (collectively, **Proposed Transaction**);
- (b) we seek the suspension to continue for one (1) trading day after, but including, the day upon which the Announcement is published on Probiomics' ASX Announcements
- (c) in regard to the event that we expect to end the requested suspension, please see our comments described in paragraph (b) immediately above;
- (d) we are not aware of any reason why the requested suspension should not be granted; and
- (e) we are not aware of any other information necessary to inform the market about the requested suspension or that has been requested by the ASX.

Yours sincerely



David P. Selig
Partner

Direct Line: (02) 8915 1010
Direct Fax: (02) 8916 2010
Email: david.selig@addisonslawyers.com.au